to characterize the subacute toxicologic and pathologic effects of human recombinant interleukin-2 ( ril-2 ) in rats , ril-2 was administered to rats at doses ranging from 3.0 to 150 x 10 ( 6 ) units/kg/day for 14 to 16 days , in once or twice daily dosing regimens by intravenous or intraperitoneal dosing routes .
C0218986
human
C0021756
ril-2